SA 11.4 Duration of endocrine therapy in early breast cancer von Huober, J.

Volltext

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 von Curigliano, G, Burstein, H.J., Winer, E.P., Gnant, M., Dubsky, P., Loibl, S., Colleoni, M., Regan, M.M., Piccart-Gebhart, M., Senn, H.-J., Thürlimann, B., André, F., Baselga, J., Bergh, J., Bonnefoi, H., Brucker, S.Y., Cardoso, F., Carey, L., Ciruelos, E., Cuzick, J., Denkert, C., Di Leo, A., Ejlertsen, B., Francis, P., Galimberti, V., Garber, J., Gulluoglu, B., Goodwin, P., Harbeck, N., Hayes, D.F., Huang, C.-S., Huober, J., Khaled, H., Jassem, J., Jiang, Z., Karlsson, P., Morrow, M., Orecchia, R., Osborne, K.C., Pagani, O., Partridge, A.H., Pritchard, K., Ro, J., Rutgers, E.J.T., Sedlmayer, F., Semiglazov, V., Shao, Z., Smith, I., Toi, M., Tutt, A., Viale, G., Watanabe, T., Whelan, T.J., Xu, B.

Volltext

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and b... von Loibl, S., Untch, M., Burchardi, N., Huober, J., Sinn, B.V., Blohmer, J.-U., Grischke, E.-M., Furlanetto, J., Tesch, H., Hanusch, C., Engels, K., Rezai, M., Jackisch, C., Schmitt, W.D., von Minckwitz, G., Thomalla, J., Kümmel, S., Rautenberg, B., Fasching, P.A., Weber, K., Rhiem, K., Denkert, C., Schneeweiss, A.

Volltext

Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response von Loibl, S., Schneeweiss, A., Huober, J., Braun, M., Rey, J., Blohmer, J.-U., Furlanetto, J., Zahm, D.-M., Hanusch, C., Thomalla, J., Jackisch, C., Staib, P., Link, T., Rhiem, K., Solbach, C., Fasching, P.A., Nekljudova, V., Denkert, C., Untch, M.

Volltext

Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from... von Geyer, C.E., Sikov, W.M., Huober, J., Rugo, H.S., Wolmark, N., O’Shaughnessy, J., Maag, D., Untch, M., Golshan, M., Lorenzo, J. Ponce, Metzger, O., Dunbar, M., Symmans, W.F., Rastogi, P., Sohn, J.H., Young, R., Wright, G.S., Harkness, C., McIntyre, K., Yardley, D., Loibl, S.

Volltext

Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial von Denkert, C., Loibl, S., Müller, B.M., Eidtmann, H., Schmitt, W.D., Eiermann, W., Gerber, B., Tesch, H., Hilfrich, J., Huober, J., Fehm, T., Barinoff, J., Jackisch, C., Prinzler, J., Rüdiger, T., Erbstößer, E., Blohmer, J.U., Budczies, J., Mehta, K.M., von Minckwitz, G.

Volltext

Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exp... von Krop, I.E., Lin, N.U., Blackwell, K., Guardino, E., Huober, J., Lu, M., Miles, D., Samant, M., Welslau, M., Diéras, V.

Volltext

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study) von Fasching, P.A., Link, T., Hauke, J., Seither, F., Jackisch, C., Klare, P., Schmatloch, S., Hanusch, C., Huober, J., Stefek, A., Seiler, S., Schmitt, W.D., Uleer, C., Doering, G., Rhiem, K., Schneeweiss, A., Engels, K., Denkert, C., Schmutzler, R.K., Hahnen, E., Untch, M., Burchardi, N., Blohmer, J.-U., Loibl, S.

Volltext

Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo von Karn, T., Denkert, C., Weber, K.E., Holtrich, U., Hanusch, C., Sinn, B.V., Higgs, B.W., Jank, P., Sinn, H.P., Huober, J., Becker, C., Blohmer, J.-U., Marmé, F., Schmitt, W.D., Wu, S., van Mackelenbergh, M., Müller, V., Schem, C., Stickeler, E., Fasching, P.A., Jackisch, C., Untch, M., Schneeweiss, A., Loibl, S.

Volltext

Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy von Lindner, J.L., Loibl, S., Denkert, C., Ataseven, B., Fasching, P.A., Pfitzner, B.M., Gerber, B., Gade, S., Darb-Esfahani, S., Sinn, B.V., Huober, J., Engels, K., Tesch, H., Karn, T., Pommerenke, F., Liedtke, C., Untch, M., Müller, V., Rack, B., Schem, C., von Minckwitz, G.

Volltext

Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44) von GERBER, B, LOIBL, S, KREIENBERG, R, SOLBACH, C, JACKISCH, C, KUNZ, G, BLOHMER, J. U, HUOBER, J, HAUSCHILD, M, NEKLJUDOVA, V, UNTCH, M, VON MINCKWITZ, G, EIDTMANN, H, REZAI, M, FASCHING, P. A, TESCH, H, EGGEMANN, H, SCHRADER, I, KITTEL, K, HANUSCH, C

Volltext

Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40—GeparQuattro) von von Minckwitz, G., Rezai, M., Fasching, P.A., Huober, J., Tesch, H., Bauerfeind, I., Hilfrich, J., Eidtmann, H., Gerber, B., Hanusch, C., Blohmer, J.U., Costa, S.D., Jackisch, C., Paepke, S., Schneeweiss, A., Kümmel, S., Denkert, C., Mehta, K., Loibl, S., Untch, M.

Volltext

Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3 von Goetz, M.P., Toi, M., Huober, J., Sohn, J., Trédan, O., Park, I.H., Campone, M., Chen, S.-C., Manso, L.M., Paluch-Shimon, S., Freedman, O.C., O’Shaughnessy, J., Pivot, X., Tolaney, S.M., Hurvitz, S.A., Llombart-Cussac, A., André, V., Saha, A., van Hal, G., Shahir, A., Iwata, H., Johnston, S.R.D.

Volltext

Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials von Huober, J., Gelber, S., Goldhirsch, A., Coates, A.S., Viale, G., Öhlschlegel, C., Price, K.N., Gelber, R.D., Regan, M.M., Thürlimann, B.

Volltext

VP6-2021: IMpassion050: A phase III study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy (neoadj A + PH + CT) in high-risk, HER2-positive early breast cancer... von Huober, J., Barrios, C.H., Niikura, N., Jarzab, M., Chang, Y-C., Huggins-Puhalla, S.L., Graupner, V., Eiger, D., Henschel, V., Gochitashvili, N., Lambertini, C., Restuccia, E., Zhang, H.

Volltext

Corrigendum to “A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinic... von Loibl, S., Untch, M., Burchardi, N., Huober, J., Sinn, B.V., Blohmer, J.-U., Grischke, E.-M., Furlanetto, J., Tesch, H., Hanusch, C., Engels, K., Rezai, M., Jackisch, C., Schmitt, W.D., von Minckwitz, G., Thomalla, J., Kümmel, S., Rautenberg, B., Fasching, P.A., Weber, K., Rhiem, K., Denkert, C., Schneeweiss, A.

Volltext

Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive met... von Huober, J, Fasching, P.A, Barsoum, M, Petruzelka, L, Wallwiener, D, Thomssen, C, Reimer, T, Paepke, S, Azim, H.A, Ragosch, V, Kubista, E, Baumgärtner, A.K, Beckmann, M.W, May, C, Nimmrich, I, Harbeck, N

Volltext

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression von Nitz, U., Gluz, O., Huober, J., Kreipe, H.H., Kates, R.E., Hartmann, A., Erber, R., Scholz, M., Lisboa, B., Mohrmann, S., Möbus, V., Augustin, D., Hoffmann, G., Weiss, E., Böhmer, S., Kreienberg, R., Du Bois, A., Sattler, D., Thomssen, C., Kiechle, M., Jänicke, F., Wallwiener, D., Harbeck, N., Kuhn, W.

Volltext

German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients von Möbus, V., von Minckwitz, G., Jackisch, C., Lück, H.-J., Schneeweiss, A., Tesch, H., Elling, D., Harbeck, N., Conrad, B., Fehm, T., Huober, J., Müller, V., Bauerfeind, I., du Bois, A., Loibl, S., Nekljudova, V., Untch, M., Thomssen, C.

Volltext

Symptoms of endocrine treatment and outcome in the BIG 1-98 study von Huober, J., Cole, B. F., Rabaglio, M., Giobbie-Hurder, A., Wu, J., Ejlertsen, B., Bonnefoi, H., Forbes, J. F., Neven, P., Láng, I., Smith, I., Wardley, A., Price, K. N., Goldhirsch, A., Coates, A. S., Colleoni, M., Gelber, R. D., Thürlimann, B.

Volltext